Indeed, since AKT phosphorylates and inactivates MAP2K4 (Park et al., 2002), breast cancer ‘driver’ mutations that activate AKT (e.g. PTEN and PI3K) also cause loss of JNK signaling. The gene discussed is MAP2K4; the disease is breast carcinoma.